Phase 3 Stomach Cancer Trial, Recruiting NCT07366528 Sponsor: Ruijin Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT07366528
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years old, of any gender
  • People who have been confirmed through laboratory testing to have a specific type of stomach or gastroesophageal junction cancer called adenocarcinoma
  • People who have already had a standard type of stomach surgery (called D2 gastrectomy) where all visible cancer was removed, and who have not had any chemotherapy or other cancer treatment before surgery
  • People whose cancer is classified as stage IIIA, IIIB, or IIIC according to a standard cancer staging system, and whose cancer tissue has been classified using a system called Lauren classification
  • People with no signs that the cancer has spread to other parts of the body
  • People who are either fully active or able to carry out light activity (rated 0 or 1 on a standard fitness scale used in cancer trials)
  • People whose blood counts, liver function, and kidney function meet specific minimum levels needed to safely tolerate the treatment (confirm with trial site for exact values)
  • Women who could become pregnant must have been using contraception for at least one month before joining, and must agree to continue using contraception throughout the study and for a set period after it ends
  • People who have read, understood, and signed a consent form, and who are willing to follow the study plan

Who may not be able to join:

  • People who have or have had another type of cancer, unless it was a fully treated skin cancer or a very early-stage cervical condition
  • People with serious health complications that may mean they are not expected to live for at least 5 more years
  • People with health conditions that are not well controlled, such as an active infection, high blood pressure, diabetes, or heart disease
  • People who are known to be allergic to the medication used in this trial
  • People who have a blockage in their bowel or any other condition that would prevent them from taking medication by mouth
  • People whose blood, liver, or kidney results show their body may not be able to handle the study treatment
  • People who the trial doctors consider unsuitable for the study for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-21-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
30 October 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

3-year disease-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov